A- A A+

NIDA. People With SUDs Have Increased Risk for COVID-19 and Worse Outcomes

This Study reported;

People with a

+ substance use disorder (SUD) at any time in their lives are 1.5 times more likely to contract COVID-19 than those without an SUD, and those with a recent SUD are more than 8 times more likely. 

+ People with opioid use disorder (OUD) and African Americans are at particularly high risk for COVID-19. 

+ COVID-19 patients with SUDs are more likely to require hospitalization and to die from COVID-19 than those without SUD, with patients with OUD and African American patients at greatest risk.

(NIDA Notes, USA, 13.01.2021)

https://www.drugabuse.gov/news-events/nida-notes/2021/01/people-with-suds-have-increased-risk-for-covid-19-worse-outcomes

Covid Reference - 6th International Edition

Bernd-Sebastian Kamps und Christoph Hoffmann

Steinhäuser Verlag, 2021

13 January 2021. Finally, after 10 weeks, we have published the next edition of COVID Reference – The COVID Textbook (453 pages; we apologize for the delay). We dedicate this edition to Anthony Fauci who never tired of defending science.

https://covidreference.com/download

For better or for worse? A pre–post exploration of the impact of the COVID‐19 lockdown on cannabis users. 

Cousijn, J., Kuhns, L., Larsen, H., and Kroon, E. (2021) 

Addiction, doi.org/10.1111/add.15387. 

https://onlinelibrary.wiley.com/doi/full/10.1111/add.15387

Science Denial and COVID Conspiracy Theories: Potential Neurological Mechanisms 

and Possible Responses. 

MILLER BL.

JAMA. 2020;324:2255-2256. 

https://jamanetwork.com/journals/jama/fullarticle/2772693

Cannabis and COVID-19: Reasons for Concern. 

van Laar MW, Oomen PE, van Miltenburg CJA, Vercoulen E, Freeman TP, Hall WD. 

Front Psychiatry. 2020 Dec 21;11:601653. doi: 10.3389/fpsyt.2020.601653. PMID: 33408655; PMCID: PMC7779403.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779403/

Experten-Web-Konferenz. Suchtbehandlung in Covid-Zeiten: der disruptive Zwang zur Innovation

JATROS Neurologie & Psychiatrie 6/20, p. 27-29

19_J_Neuro_Kon_ÖGABS Experten-Web-Konferenz_Barth final

Impact of the COVID-19 Pandemic on Patients With Alcohol Use Disorder and Associated Risk Factors for Relapse. 

Yazdi K, Fuchs-Leitner I, Rosenleitner J, Gerstgrasser NW. 

Front Psychiatry. 2020 Dec 16;11:620612. doi: 10.3389/fpsyt.2020.620612. PMID: 33391060; PMCID: PMC7772314.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772314/

HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform

Bhaskaran, Krishnan et al.

The Lancet HIV, Volume 8, Issue 1, e24 - e32 

https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(20)30305-2/fulltext

Prioritizing incarcerated populations for COVID-19 vaccination and vaccine trials

Kronfli, Nadine et al.

EClinicalMedicine, Volume 31, 100659 

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30403-X/fulltext

How Covid-19 has fueled unprecedented advances in medicine

The Covid-19 pandemic has reshaped the world of health and medicine. New vaccines are being developed at a pace once unimaginable. Telemedicine has replaced the doctor’s office for many. And artificial intelligence is predicting the patients at highest risk of growing severely ill. (stat ebook, USA, 06.01.2021)

https://www.statnews.com/covid-19-advances-in-medicine

Does opioid substitution treatment have a protective effect on the clinical manifestations of COVID-19? Comment on Br J Anaesth 2020; 125: e382-3. 

Eagleton M, Stokes S, Fenton F, Keenan E. 

Br J Anaesth. 2020 Nov 28:S0007-0912(20)30949-1. doi: 10.1016/j.bja.2020.11.027. Epub ahead of print. PMID: 33358041; PMCID: PMC7699021.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699021/

Down the drain: Reconsidering routine urine drug testing during the COVID-19 pandemic. 

Pytell JD, Rastegar DA. 

J Subst Abuse Treat. 2021 Jan;120:108155. doi: 10.1016/j.jsat.2020.108155. Epub 2020 Oct 5. PMID: 33298297; PMCID: PMC7534596.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534596/

Review of opioid risk assessment tools with the growing need for telemedicine. 

Ogilvie CB, Jotwani R, Joshi J, Gulati A, Mehta N. 

Pain Manag. 2020 Dec 22. doi: 10.2217/pmt-2020-0064. Epub ahead of print. PMID: 33350355.

https://www.futuremedicine.com/doi/10.2217/pmt-2020-0064

Can Kratom (Mitragyna speciosa) Alleviate COVID-19 Pain? A Case Study. 

Metastasio A, Prevete E, Singh D, Grundmann O, Prozialeck WC, Veltri C, Bersani G, Corazza O. 

Front Psychiatry. 2020 Nov 19;11:594816. doi: 10.3389/fpsyt.2020.594816. PMID: 33329145; PMCID: PMC7717955.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717955/

Current and Future Potential Impact of COVID-19 on Kratom (Mitragyna speciosa Korth.) Supply and Use. 

Singh D, Brown PN, Cinosi E, Corazza O, Henningfield JE, Garcia-Romeu A, McCurdy CR, McMahon LR, Prozialeck WC, Smith KE, Swogger MT, Veltri C, Walsh Z, Grundmann O. 

Front Psychiatry. 2020 Nov 26;11:574483. doi: 10.3389/fpsyt.2020.574483. PMID: 33324252; PMCID: PMC7726130.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726130/

The Healthy Brain and Child Development Study-Shedding Light on Opioid Exposure, COVID-19, and Health Disparities. 

Volkow ND, Gordon JA, Freund MP. 

JAMA Psychiatry. 2020 Dec 9. doi: 10.1001/jamapsychiatry.2020.3803. Epub ahead of print. PMID: 33295951.

https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2774000

Global Perspective and Ways to Combat Stigma Associated with COVID-19. 

Adiukwu F, Bytyçi DG, Hayek SE, Gonzalez-Diaz JM, Larnaout A, Grandinetti P, Nofal M, Pereira-Sanchez V, Ransing R, Shalbafan M, Soler-Vidal J, Syarif Z, Teixeira ALS, da Costa MP, Ramalho R, Orsolini L. 

Indian J Psychol Med. 2020 Nov 9;42(6):569-574. doi: 10.1177/0253717620964932. PMID: 33354085; PMCID: PMC7735248.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735248/

Monitoring drug consumption in Innsbruck during coronavirus disease 2019 (COVID-19) lockdown by wastewater analysis. 

Kreidl M, Huber S, Grander J, Haslacher S, Singer K, Schlapp-Hackl M, Sorg M, Erber H, Oberacher H. 

Sci Total Environ. 2020 Nov 23;757:144006. doi: 10.1016/j.scitotenv.2020.144006. Epub ahead of print. PMID: 33310574; PMCID: PMC7681035.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681035/

Trajectories of anxiety and depressive symptoms during enforced isolation due to COVID-19 in England: a longitudinal observational study

Fancourt, Daisy et al.

The Lancet Psychiatry, Volume 0, Issue 0 

https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(20)30482-X/fulltext

Rethinking Covid-19 Test Sensitivity - A Strategy for Containment. 

Mina MJ, Parker R, Larremore DB. 

N Engl J Med. 2020 Nov 26;383(22):e120. doi: 10.1056/NEJMp2025631. Epub 2020 Sep 30. PMID: 32997903.

https://www.nejm.org/doi/10.1056/NEJMp2025631

Impacts of COVID-19 on residential treatment programs for substance use disorder. 

Pagano A, Hosakote S, Kapiteni K, Straus ER, Wong J, Guydish JR. 

J Subst Abuse Treat. 2020 Dec 17:108255. doi: 10.1016/j.jsat.2020.108255. Epub ahead of print. PMID: 33375986.

https://www.journalofsubstanceabusetreatment.com/article/S0740-5472(20)30512-2/fulltext

Association of substance use disorders and drug overdose with adverse COVID-19 outcomes in New York City: January-October 2020. 

Allen B, El Shahawy O, Rogers ES, Hochman S, Khan MR, Krawczyk N. 

J Public Health (Oxf). 2020 Dec 26:fdaa241. doi: 10.1093/pubmed/fdaa241. Epub ahead of print. PMID: 33367823.

https://academic.oup.com/jpubhealth/advance-article/doi/10.1093/pubmed/fdaa241/6047762

Impact of COVID-19 Pandemic on Drug Overdoses in Indianapolis. 

Glober N, Mohler G, Huynh P, Arkins T, O'Donnell D, Carter J, Ray B. 

J Urban Health. 2020 Dec;97(6):802-807. doi: 10.1007/s11524-020-00484-0. Epub 2020 Oct 1. PMID: 33005988; PMCID: PMC7529089.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529089/

COVID-19 survey among people who use drugs in three cities in Norway. 

Welle-Strand GK, Skurtveit S, Clausen T, Sundal C, Gjersing L. 

Drug Alcohol Depend. 2020 Dec 1;217:108302. doi: 10.1016/j.drugalcdep.2020.108302. Epub 2020 Sep 18. PMID: 32961453; PMCID: PMC7500397.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500397/

A double-edged sword of using opioids and COVID-19: a toxicological view. 

Ataei M, Shirazi FM, Lamarine RJ, Nakhaee S, Mehrpour O. A 

Subst Abuse Treat Prev Policy. 2020 Dec 3;15(1):91. doi: 10.1186/s13011-020-00333-y. PMID: 33272308; PMCID: PMC7711252.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711252/

Multiple potential targets of opioids in the treatment of acute respiratory distress syndrome from COVID-19. 

Cismaru CA, Cismaru GL, Nabavi SF, Ghanei M, Burz CC, Nabavi SM, Berindan Neagoe I. 

J Cell Mol Med. 2020 Nov 19:10.1111/jcmm.15927. doi: 10.1111/jcmm.15927. Epub ahead of print. PMID: 33211389; PMCID: PMC7753383.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753383/

Clinical Trials for Substance Use Disorders in the Age of Covid-19. 

Brezing CA, Luo SX, Mariani JJ, Levin FR. Digital 

J Addict Med. 2020 Dec;14(6):e297-e302. doi: 10.1097/ADM.0000000000000733. PMID: 32956164; PMCID: PMC7647443.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647443/

'The dual pandemic' of suicide and COVID-19: A biopsychosocial narrative of risks and prevention. 

Banerjee D, Kosagisharaf JR, Sathyanarayana Rao TS.

Psychiatry Res. 2020 Nov 18:113577. doi: 10.1016/j.psychres.2020.113577. Epub ahead of print. PMID: 33229123; PMCID: PMC7672361.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672361/

Telepsychiatry and Addiction Treatment. 

Mohan A, Ambekar A. 

Indian J Psychol Med. 2020 Oct 6;42(5 Suppl):52S-56S. doi: 10.1177/0253717620958169. PMID: 33354065; PMCID: PMC7736732.

https://journals.sagepub.com/doi/10.1177/0253717620958169

Drug use during a pandemic: Convergent risk of novel coronavirus and invasive bacterial and viral infections among people who use drugs. 

Jacka BP, Phipps E, Marshall BDL. 

Int J Drug Policy. 2020 Sep;83:102895. doi: 10.1016/j.drugpo.2020.102895. Epub 2020 Jul 29. PMID: 32741718; PMCID: PMC7388892.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388892/